# To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

> **NCT04853342** · PHASE3 · RECRUITING · sponsor: **Allist Pharmaceuticals, Inc.** · enrollment: 318 (estimated)

## Conditions studied

- Non-small Cell Lung Carcinoma

## Interventions

- **DRUG:** Drug: Furmonertinib 80 mg
- **DRUG:** Furmonertinib 80 mg placebo

## Key facts

- **NCT ID:** NCT04853342
- **Lead sponsor:** Allist Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-07
- **Primary completion:** 2026-01
- **Final completion:** 2030-01
- **Target enrollment:** 318 (ESTIMATED)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04853342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04853342, "To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04853342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*